Compare Twist Bioscience Corp (TWST) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Block Inc — how do they compare? Twist Bioscience Corp trades at $160.14 (market cap $10.08B), while Block Inc trades at $77.25 (market cap $45.20B). The key difference: Block Inc is far larger — about 4.5× Twist Bioscience Corp's market cap, and Block Inc is more actively traded (8,386,094 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Block Inc for 78 Days on average.
| TWST | XYZ | |
|---|---|---|
Market Cap | $10.08B | $45.20B |
Volume | 4,229,037 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $205.00 | $84.85 |
52-Week Low | $25.45 | $49.04 |
Typical Hold Time | 27 Days | 78 Days |
Enterprise Value | $10.01B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Block (XYZ) trades at $77.09, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but faces profitability challenges with a net margin of just 1.43%. Recent developments include expanding Square and Cash App partnerships with Apple and Workday, while pursuing a national trust bank charter to reduce third-party banking costs.
The stock offers 26% upside to the $97.47 consensus target with strong analyst support (77% buy ratings), though high P/E of 134.34 raises valuation concerns. Key risks include declining net income margins, insider selling activity, and competitive fintech pressures. The upcoming Q3 2026 earnings report on November 3rd will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
